2 unchanged sentences
Our management, Chief Executive Officer and Principal Financial and Accounting Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2023.
−Removed: The term "disclosure controls and procedures,"
−Removed: as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.
+Added: The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, as appropriate, to allow timely decisions regarding required disclosure.
60 unchanged sentences
filed January 23, 2023, File No.
+Added: Certificate of Designation of Series G Convertible Preferred Stock.
+Added: (incorporated by reference to Exhibit 3.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed May 9, 2023, File No.
+Added: Certificate of Designation of Series H Convertible Preferred Stock.
+Added: (incorporated by reference to Exhibit 3.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed July 3, 2023, File No.
+Added: Certificate of Designation of Series I Convertible Preferred Stock.
+Added: (incorporated by reference to Exhibit 3.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
+Added: Certificate of Designation of Series J Convertible Preferred Stock.
+Added: (incorporated by reference to Exhibit 3.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed March 1, 2024, File No.
Specimen Non-Voting Common Stock Certificate of Jaguar Health, Inc.
73 unchanged sentences
filed August 30, 2022, File No.
+Added: Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed May 9, 2023, File No.
+Added: Global Amendment No.
+Added: 2, dated September 29, 2023, by and between Jaguar Health, Inc.
+Added: and Iliad Research and Trading, L.P.
+Added: (incorporated by reference to Exhibit 4.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
+Added: Global Amendment No.
+Added: 2, dated September 29, 2023, by and between Jaguar Health, Inc.
+Added: and Uptown Capital, LLC (incorporated by reference to Exhibit 4.2 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
+Added: Global Amendment, dated September 29, 2023, by and between Jaguar Health, Inc.
+Added: and Streeterville Capital, LLC (incorporated by reference to Exhibit 4.3 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
+Added: Global Amendment No.
+Added: 2, dated September 29, 2023, by and between Jaguar Health, Inc.
+Added: and Streeterville Capital, LLC (incorporated by reference to Exhibit 4.4 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
+Added: Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.5 to the Form 8-K of Jaguar Health, Inc.
+Added: filed October 5, 2023, File No.
Form of Indemnification Agreement by and between Jaguar Health, Inc.
218 unchanged sentences
filed February 6, 2023, File No.
−Removed: Letter from Mayer Hoffman McCann P.C., dated November 23, 2021 (incorporated by reference to Exhibit 16.1 to the Form 8-K of Jaguar Health, Inc.
−Removed: filed November 23, 2021, File No.
+Added: Form of Securities Purchase Agreement, dated May 8, 2023 (incorporated by reference to Exhibit 10.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed May 9, 2023, File No.
+Added: Standstill Agreement, dated May 8, 2023 (incorporated by reference to Exhibit 10.2 to the Form 8-K of Jaguar Health, Inc.
+Added: filed May 9, 2023, File No.
+Added: Second Amendment to the Jaguar Health, Inc.
+Added: New Employee Inducement Award Plan (incorporated by reference to Exhibit 10.1 to the Form 8-K of Jaguar Health, Inc.
+Added: filed May 19, 2023, File No.
+Added: Form of Exchange Agreement, dated June 28, 2023, by and between Jaguar Health, Inc.
+Added: and Uptown Capital, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed July 3, 2023, File No.
+Added: First Amendment to the Standstill Agreement, dated June 28, 2023 (incorporated by reference to Exhibit 10.2 to the Form 8-K of Jaguar Health, Inc.
+Added: filed July 3, 2023, File No.
+Added: Binding Memorandum of Understanding, dated June 30, 2023, by and among Jaguar Health, Inc., Napo Pharmaceuticals, Inc., Iliad Research and Trading, L.P., Uptown Capital, LLC and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.6 to the Form 10-Q filed August 14, 2023, File No.
+Added: Amendment No.
+Added: 1 to Manufacturing and Supply Agreement, dated July 12, 2023, by and between Napo Pharmaceuticals, Inc.
+Added: and Glenmark Life Sciences Limited (incorporated by reference to Exhibit 10.7 to the Form 10-Q filed August 14, 2023, File No.
+Added: Exchange Agreement, dated September 29, 2023, by and between Jaguar Health, Inc.
+Added: and Uptown Capital, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed October 5, 2023, File No.
+Added: First Amendment to 200 Pine Street Office Lease, dated December 24, 2021, between Jaguar Health, Inc.
+Added: and M & E, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed December 1, 2023, File No.
+Added: Second Amendment to 200 Pine Street Office Lease, dated October 25, 2023, between Jaguar Health, Inc.
+Added: and M & E, LLC (incorporated by reference to Exhibit 10.2 to the Form 8-K filed December 1, 2023, File No.
+Added: Exchange Agreement, dated March 1, 2024, by and between Jaguar Health, Inc.
+Added: and Streeterville Capital, LLC (incorporated by reference to Exhibit 10.1 to the Form 8-K filed March 1, 2024, File No.
+Added: Form of PIPE Warrant Exchange Agreement, dated February 27, 2024, by and between Jaguar Health, Inc.
+Added: and the PIPE investor (incorporated by reference to Exhibit 10.2 to the Form 8-K filed March 1, 2024, File No.
Subsidiaries of the Registrant.
Consent of RBSM LLP, Independent Registered Public Accounting Firm.
−Removed: Consent of Mayer Hoffman McCann P.C., Independent Registered Public Accounting Firm.
Principal Executive Officer’s Certifications Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
§ 1350 (Section 906 of Sarbanes-Oxley Act of 2002).
+Added: Jaguar Health, Inc.
+Added: Clawback Policy
Inline XBRL Instance Document
21 unchanged sentences
Chief Executive Officer, President and Director (Principal Executive Officer)
−Removed: March 24, 2023
+Added: April 1, 2024
/s/ CAROL LIZAK
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
−Removed: March 24, 2023
+Added: April 1, 2024
Chairman of the Board
−Removed: March 24, 2023
+Added: April 1, 2024
/s/ JOHN MICEK III
John Micek III
−Removed: March 24, 2023
+Added: April 1, 2024
/s/ JONATHAN B.
−Removed: March 24, 2023
+Added: April 1, 2024
/s/ ANULA JAYASURIYA
Anula Jayasuriya
−Removed: March 24, 2023
+Added: April 1, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.